2. UroToday Home
  3. Conference Highlights
  4. ESMO 2018
  5. ESMO 2018 Press Releases

ESMO 2018

Bayer to Showcase Latest Oncology Research at ESMO 2018 Congress

San Francisco, CA USA (UroToday.com) --  Bayer will present new data from the company's growing oncology portfolio at the ESMO 2018 Congress (European Society for Medical Oncology) taking place October 19-23 in Munich, Germany. Among the research presented will be an expanded pivotal trial data set on larotrectinib, a TRK (tropomyosin receptor kinase) inhibitor in development for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.

Larotrectinib is currently under review by the U.S. Food and Drug Administration and the European Medicines Agency, with additional filings in other countries underway or being planned. The oral presentation will provide updated clinical follow-up for the 55 patients who comprise the combined efficacy analysis population that supports these global regulatory filings and new data for patients subsequently enrolled.

"We look forward to sharing the latest data across our oncology portfolio including new research in precision medicine," said Scott Z. Fields, M.D., Senior Vice President and Head of Oncology Development at Bayer. "The data at ESMO reinforce Bayer's commitment to advancing cancer therapies to drive meaningful progress for patients."

Bayer will also present a combined Phase I and II analysis of copanlisib, its PI3K inhibitor with inhibitory activity predominantly against the PI3K-alpha and PI3K-delta isoforms, in patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma, and new data on rogaratinib in patients with FGFR mRNA-positive head and neck cancer.

In addition, findings from the Phase III ERA-223 trial investigating the use of radium Ra 223 dichloride injection in combination with abiraterone acetate and prednisone/prednisolone in asymptomatic or minimially symptomatic patients with metastatic castration-resistant prostate cancer (mCRPC) will be presented as well as interim results from the prospective, Phase III non-interventional PARABO study examining symptomatic skeletal event (SSE) dynamics in mCRPC patients treated with radium Ra 223 dichloride injection.

Data to be presented on regorafenib include the final results from a prospective, observational study (CORRELATE) analyzing real-world dosing in metastatic colorectal cancer (mCRC) patients.

Notable studies from Bayer's portfolio and pipeline therapies being featured at the ESMO 2018 Congress are listed below:

Radium Ra 223 Dichloride (radium-223)
  • ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone (abi) and prednisone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer
  • Late Breaking Abstract 30, Proffered Paper Session - Genitourinary tumours, prostate; October 19, 2018, 2:00 – 3:30 pm CEST; ICM - Room 13
  • Radium-223 (Ra-223) therapy after abiraterone (Abi): analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
  • Abstract 824P, Poster Display Session; October 22, 2018, 12:45 – 1:45 pm CEST; Hall A3
  • Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE
  • Abstract 826P, Poster Display Session; October 22, 2018, 12:45 – 1:45 pm CEST; Hall A3
  • Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study using real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC)
  • Abstract 827P, Poster Display Session; October 22, 2018,12:45 – 1:45 pm CEST; Hall A3
  • Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An interim review of a prospective, non-interventional study (PARABO) 
  • Abstract 828P, Poster Display Session; October 22, 2018, 12:45 – 1:45 pm CEST; Hall A3
Regorafenib
  • Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
  • Abstract: 463P, Poster Display Session; October 21, 12:45 – 1:45 pm CEST; Hall A3
  • Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib
  • Abstract: 473P, Poster Display Session; October 21, 12:45 – 1:45 pm CEST; Hall A3
  • Analysis of single-nucleotide polymorphisms (SNPs) in the phase 3 RESORCE trial of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC)
  • Abstract: 701P, Poster Display Session; October 21, 12:45 – 1:45 pm CEST; Hall A3
  • Identification of drug combinations with regorafenib (REG) for the treatment of pediatric rhabdomyosarcomas (RMS)
  • Abstract: 1644P, Poster Display Session; October 22, 12:45 – 1:45 pm CEST; Hall A3
Sorafenib
  • Practice Patterns and Deterioration of Liver Function after Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): Final Analysis of OPTIMIS in Europe and Canada
  • Abstract: 710P, Poster Display Session; October 21, 12:45 – 1:45 pm CEST; Hall A3
Larotrectinib
  • Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach
  • Abstract 409O; Proffered Paper Session - Developmental therapeutics; October 21, 2018; 11:00 am – 12:30 pm CEST; Hall B3, Room 22
Copanlisib
  • PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
  • Abstract 67P, Poster Display Session; October 20, 12:30 – 1:30 pm CEST; Hall A3
  • Copanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: combined analysis from phase I and II studies
  • Abstract 1006O, Oral Presentation; October 21, 11:00 am – 12:30 pm CEST; Hall B4, Room 19
Rogaratinib
  • Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression
  • Abstract: 1056PD, Poster Discussion Session; October 20, 3:00 – 4:00 pm CEST; Hall B3, Room 23
  • Phase 1b/2 study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression
  • Abstract: 925TiP, Poster Display Session; October 22, 12:45 – 1:45 pm CEST; Hall A3
  • Phase 2/3 study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression
  • Abstract: 930TiP, Poster Display Session; October 22, 12:45 – 1:45 pm CEST; Hall A3
Further Related Content:
Complete ESMO 2018 Conference Coverage